Metabolic Disorder Therapeutics Market

Metabolic Disorder Therapeutics Market contains market size and forecasts of Metabolic Disorder Therapeutics in Global, including the following market information:

Global Metabolic Disorder Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Metabolic Disorder Therapeutics market was valued at 48030 million in 2021 and is projected to reach US$ 63690 million by 2028, at a CAGR of 4.1% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Lysosomal Storage Diseases Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Metabolic Disorder Therapeutics include Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck KgaA, Amgen, Inc., AstraZeneca PLC, Actelion Pharmaceuticals Ltd. and Shire PLC, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Metabolic Disorder Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Metabolic Disorder Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Metabolic Disorder Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Lysosomal Storage Diseases
• Diabetes
• Obesity
• Inherited Metabolic Disorders
• Hypercholesterolemia

Global Metabolic Disorder Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Metabolic Disorder Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Oral
• Parenteral
• Others

Global Metabolic Disorder Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Metabolic Disorder Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Metabolic Disorder Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Metabolic Disorder Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Novo Nordisk A/S
• Sanofi S.A.
• Boehringer Ingelheim GmbH
• Eli Lilly and Company
• Merck KgaA
• Amgen, Inc.
• AstraZeneca PLC
• Actelion Pharmaceuticals Ltd.
• Shire PLC
• AbbVie, Inc.
• Biocon Ltd.
• BioMarin Pharmaceutical, Inc.
• Bristol-Myers Squibb Company
• Cipla, Inc.
• CymaBay Therapeutics, Inc.